Cytokinetics (CYTK) EVP sells 3,639 shares, retains 66,004

Rhea-AI Filing Summary

Cytokinetics EVP and Chief Commercial Officer Andrew Callos sold 3,639 shares of Common Stock in an open-market transaction at $65.00 per share. The sale occurred on March 31, 2026. After this transaction, he continues to hold 66,004 shares of Cytokinetics Common Stock directly.

Insider Trade Summary 10b5-1

Net Seller: 3,639 shares ($236,535)

Net Sell 1 txn

Insider Callos Andrew

Role EVP, Chief Commercial Officer

Sold 3,639 shs ($237K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,639	$65.00	$237K

Holdings After Transaction: Common Stock — 66,004 shares (Direct)

Footnotes (1)

Key Figures

Shares sold: 3,639 shares Sale price: $65.00 per share Shares held after transaction: 66,004 shares +1 more

4 metrics

Shares sold 3,639 shares Open-market sale of Common Stock

Sale price $65.00 per share Price for the 3,639 shares sold

Shares held after transaction 66,004 shares Direct holdings following the sale

Transactions classified as sales 1 transaction Form 4 transaction summary

Key Terms

Common Stock, open-market sale, Form 4, EVP, Chief Commercial Officer

4 terms

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

EVP, Chief Commercial Officer financial

"officer_title: "EVP, Chief Commercial Officer""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Callos Andrew

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		S		3,639	D	$65	66,004	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Mr. Callos	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CYTK executive Andrew Callos report?

Andrew Callos reported an open-market sale of 3,639 shares of Cytokinetics Common Stock at $65.00 per share. The transaction reflects a standard Form 4 disclosure of activity by the company’s EVP and Chief Commercial Officer.

How many CYTK shares did Andrew Callos sell and at what price?

He sold 3,639 shares of Cytokinetics Common Stock at $65.00 per share. This was an open-market sale reported on Form 4, detailing the price and share count for investors tracking insider trading activity.

How many CYTK shares does Andrew Callos hold after this sale?

Following the reported sale, Andrew Callos directly holds 66,004 shares of Cytokinetics Common Stock. This post-transaction balance comes from the Form 4 and shows his remaining direct equity stake in the company.

What role does Andrew Callos hold at Cytokinetics (CYTK)?

Andrew Callos serves as Executive Vice President and Chief Commercial Officer at Cytokinetics. His Form 4 filing discloses personal equity transactions in the company’s Common Stock in his capacity as a reporting officer.

Was the CYTK insider transaction an open-market sale or another type?

The CYTK insider transaction was an open-market sale of Common Stock. The Form 4 uses transaction code "S" and describes it as a sale in an open market or private transaction at a price of $65.00 per share.